Crown Laboratories Completes Acquisition of Revance Therapeutics

Crown Laboratories, Inc. has successfully closed its acquisition of biotechnology company Revance Therapeutics, Inc.

The entities first announced the merger agreement – a deal valued at $924 million – in August 2024.

Jeff Bedard, founder and CEO of Crown, previously said the combined entities would be afforded the opportunity to create a comprehensive portfolio of high-growth products for all stages of life, and that as a unit, would be committed to investing in education, training and practice support for aesthetics providers across the US.

Based in Nashville, TN, Revance is a Nasdaq-traded company whose portfolio includes Daxxify (DaxibotulinumtoxinA-lanm), an FDA -pproved injectable peptide formulated neuromodulator that competes with Botox, and the RHA Collection, an FDA approved hyaluronic acid filler line.

Revance’s common stock will be delisted from the NASDAQ Global Select Market and deregistered under the Securities Exchange Act of 1934, as amended.